M E Kraenzlin

Summary

Affiliation: University of Basel
Country: Switzerland

Publications

  1. ncbi request reprint Use of beta-blockers and risk of fractures
    Raymond G Schlienger
    Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital, Basel, Switzerland
    JAMA 292:1326-32. 2004
  2. ncbi request reprint Use of recombinant human thyroid-stimulating hormone in the management of well-differentiated thyroid cancer
    Marius E Kraenzlin
    University Hospital Basel, Clinic for Endocrinology, Diabetes and Clinical Nutrition, Missionsstrasse 24, CH 4055 Basel, Switzerland
    Expert Opin Biol Ther 6:167-76. 2006
  3. ncbi request reprint Practical use of biochemical markers of bone turnover
    M E Kraenzlin
    Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Basel, Basel, Switzerland
    Ann Endocrinol (Paris) 67:155-6. 2006
  4. ncbi request reprint [Swiss guidance for the diagnosis and management of osteoporosis]
    M E Kraenzlin
    Clinique d Endocrinologie, diabetologie et metabolisme, Hôpital universitaire de Bâle, Spitalstrasse 21 Petersgraben 4, 4031 Bâle
    Rev Med Suisse 9:1272, 1274-8. 2013
  5. pmc Phenotypic variability of the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA): clinical, molecular and biochemical delineation
    Marianne Rohrbach
    Division of Metabolism, University Children s Hospital and Children s Research Centre, Zurich, Switzerland
    Orphanet J Rare Dis 6:46. 2011
  6. ncbi request reprint [Diagnosis of osteoporosis. How do you manage it?]
    M E Kraenzlin
    Abteilung Endokrinologie, Kantonsspital Basel, Schweiz
    MMW Fortschr Med 144:24-30. 2002
  7. doi request reprint Possible beneficial effect of bisphosphonates in osteonecrosis of the knee
    Marius E Kraenzlin
    Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital, 4031 Basel, Switzerland
    Knee Surg Sports Traumatol Arthrosc 18:1638-44. 2010
  8. doi request reprint [Laboratory assessment of osteoporosis]
    Marius E Kraenzlin
    Klinik fur Endokrinologie, Diabetes und klinische Ernährung, Universitatsspital Basel, Basel und Endokrinologische Praxis und Labor, Basel
    Ther Umsch 65:513-8. 2008
  9. doi request reprint Automated HPLC assay for urinary collagen cross-links: effect of age, menopause, and metabolic bone diseases
    Marius E Kraenzlin
    Division of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital, CH 4031 Basel, Switzerland
    Clin Chem 54:1546-53. 2008
  10. ncbi request reprint [Thiazolidinediones and skeletal health]
    C Meier
    Division d endocrinologie, diabète et nutrition clinique, Hôpital universitaire de Bâle, Bale
    Rev Med Suisse 5:1309-10, 1312-3. 2009

Collaborators

Detail Information

Publications16

  1. ncbi request reprint Use of beta-blockers and risk of fractures
    Raymond G Schlienger
    Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital, Basel, Switzerland
    JAMA 292:1326-32. 2004
    ....
  2. ncbi request reprint Use of recombinant human thyroid-stimulating hormone in the management of well-differentiated thyroid cancer
    Marius E Kraenzlin
    University Hospital Basel, Clinic for Endocrinology, Diabetes and Clinical Nutrition, Missionsstrasse 24, CH 4055 Basel, Switzerland
    Expert Opin Biol Ther 6:167-76. 2006
    ..In addition, rhTSH has potential for use in facilitating the treatment of metastasis in patients with DTC and in patients with non-toxic nodular goiter; however, more clinical trials are needed to confirm its use in these situations...
  3. ncbi request reprint Practical use of biochemical markers of bone turnover
    M E Kraenzlin
    Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Basel, Basel, Switzerland
    Ann Endocrinol (Paris) 67:155-6. 2006
  4. ncbi request reprint [Swiss guidance for the diagnosis and management of osteoporosis]
    M E Kraenzlin
    Clinique d Endocrinologie, diabetologie et metabolisme, Hôpital universitaire de Bâle, Spitalstrasse 21 Petersgraben 4, 4031 Bâle
    Rev Med Suisse 9:1272, 1274-8. 2013
    ..This should allow one to better identify the subjects with increased fracture risk and offering them effective treatment...
  5. pmc Phenotypic variability of the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA): clinical, molecular and biochemical delineation
    Marianne Rohrbach
    Division of Metabolism, University Children s Hospital and Children s Research Centre, Zurich, Switzerland
    Orphanet J Rare Dis 6:46. 2011
    ..Severe hypotonia usually leads to delay in gross motor development, whereas cognitive development is reported to be normal...
  6. ncbi request reprint [Diagnosis of osteoporosis. How do you manage it?]
    M E Kraenzlin
    Abteilung Endokrinologie, Kantonsspital Basel, Schweiz
    MMW Fortschr Med 144:24-30. 2002
    ..Currently, such biochemical markers as osteocalcin or hydroxyproline are being investigated for their diagnostic value in terms of disease activity fracture risk and the monitoring of treatment...
  7. doi request reprint Possible beneficial effect of bisphosphonates in osteonecrosis of the knee
    Marius E Kraenzlin
    Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital, 4031 Basel, Switzerland
    Knee Surg Sports Traumatol Arthrosc 18:1638-44. 2010
    ..Further randomized, controlled trials are warranted to confirm the potential beneficial role of bisphosphonates in the treatment of osteonecrosis of the knee. Level of evidence: observational study, level IV...
  8. doi request reprint [Laboratory assessment of osteoporosis]
    Marius E Kraenzlin
    Klinik fur Endokrinologie, Diabetes und klinische Ernährung, Universitatsspital Basel, Basel und Endokrinologische Praxis und Labor, Basel
    Ther Umsch 65:513-8. 2008
    ..Repeated measurements of biochemical markers during treatment appear to improve the management of osteoporotic patients...
  9. doi request reprint Automated HPLC assay for urinary collagen cross-links: effect of age, menopause, and metabolic bone diseases
    Marius E Kraenzlin
    Division of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital, CH 4031 Basel, Switzerland
    Clin Chem 54:1546-53. 2008
    ..We evaluated the analytical and clinical performance of a commercially available PYD HPLC assay and established reference intervals in children and adults...
  10. ncbi request reprint [Thiazolidinediones and skeletal health]
    C Meier
    Division d endocrinologie, diabète et nutrition clinique, Hôpital universitaire de Bâle, Bale
    Rev Med Suisse 5:1309-10, 1312-3. 2009
    ..As a consequence of these observations, clinicians have to carefully assess the fracture risk in patients with type 2 diabetes before starting a therapy with thiazolidinediones...
  11. ncbi request reprint HMG-CoA reductase inhibitors and the risk of fractures
    C R Meier
    Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology, University Hospital of Basel, Petersgraben 4, CH 4031, Basel, Switzerland
    JAMA 283:3205-10. 2000
    ..It is unknown whether use of statins is associated with a decreased risk of fractures in humans...
  12. doi request reprint Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice
    Christina Keel
    Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Basel, Missionsstrasse 24, 4055 Basel, Switzerland
    J Bone Miner Metab 28:68-76. 2010
    ..Furthermore, as bisphosphonate wash-out does not appear to influence the treatment effect, teriparatide therapy can be started immediately after ceasing bisphosphonate therapy and wash-out...
  13. doi request reprint Use of thiazolidinediones and fracture risk
    Christian Meier
    Division of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital Basel, Hebelstrasse 2, CH 4031 Basel, Switzerland
    Arch Intern Med 168:820-5. 2008
    ..Thiazolidinediones may adversely affect the skeleton owing to decreased bone formation and accelerated bone loss...
  14. ncbi request reprint [Diagnosis of osteoporosis]
    Marius E Kraenzlin
    Rev Med Suisse Romande 122:395-7. 2002
  15. ncbi request reprint Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy
    Albrecht W E Popp
    Osteoporosis Policlinic, University Hospital of Berne, Switzerland
    Maturitas 53:191-200. 2006
    ..The effects on bone of such long-cycle HRT regimens are unknown. The objective of the present study was to compare the effects on bone and the endometrium of long-cycle HRT and conventional HRT...
  16. ncbi request reprint An automated 'bio-intact' PTH assay: a step towards standardisation and improved correlation with parathyroid function in renal disease
    Reto Savoca
    Center for Laboratory Medicine, Kantonspital Aarau, CH 5001, Aarau, Switzerland
    Clin Chim Acta 343:167-71. 2004
    ..Most methods for the determination of parathyroid hormone (PTH) show cross-reactivity with N-truncated forms of PTH. The analytic and diagnostic value of a recently developed automated PTH test without this cross-reactivity was examined...